Genticel's ProCervix misses HPV endpoint

Genticel S.A. (Euronext:GTCL) said ProCervix ( GTL001) missed the primary endpoint in the European Phase II RHEIA-VAC trial, which evaluated the potential of the bivalent therapeutic vaccine to prevent cervical cancer by enhancing immune response to HPV. The vaccine failed to improve viral clearance at 12 months postvaccination vs. placebo (48.7% for ProCervix vs. 39.7% for placebo, p=0.11).

ProCervix is a vaccine against HPV types 16 and 18, which Genticel said are the two most oncogenic HPV strains and which account for about 70% of cervical cancer cases. ...